Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bensen

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Medchemcomm|September 20, 2019
FgaPT2, a biocatalytic tool for alkyl-diversification of indole natural productsChandrasekhar Bandari, Erin M Scull, Tejaswi Bavineni, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2006
Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitorsLeslie W Tari, Isaac D Hoffman, Daniel C Bensen, et al.
Applied and Environmental Microbiology|January 5, 2002
Comparative genomic analysis of archaeal genotypic variants in a single population and in two different oceanic provincesOded Béjà, Eugene V Koonin, L Aravind, et al.
ACS Pharmacology & Translational Science|February 22, 2021
Single Cell Mass Spectrometry Quantification of Anticancer Drugs: Proof of Concept in Cancer PatientsRyan C Bensen, Shawna J Standke, Devon H Colby, et al.
Antiviral Research|July 5, 2019
Differing activities of oxysterol-binding protein (OSBP) targeting anti-viral compoundsBrett L Roberts, Zachary C Severance, Ryan C Bensen, et al.
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.
Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.
ACS Chemical Biology|December 22, 2018
Transient Compound Treatment Induces a Multigenerational Reduction of Oxysterol-Binding Protein (OSBP) Levels and Prophylactic Antiviral ActivityBrett L Roberts, Zachary C Severance, Ryan C Bensen, et al.
Journal of Medicinal Chemistry|March 14, 2023
Structure-Activity Relationships of Ligand Binding to Oxysterol-Binding Protein (OSBP) and OSBP-Related Protein 4Zachary C Severance, Juan I Nuñez, Anh T Le-McClain, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2013
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activityLeslie W Tari, Michael Trzoss, Daniel C Bensen, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Medchemcomm|September 20, 2019
FgaPT2, a biocatalytic tool for alkyl-diversification of indole natural productsChandrasekhar Bandari, Erin M Scull, Tejaswi Bavineni, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2006
Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitorsLeslie W Tari, Isaac D Hoffman, Daniel C Bensen, et al.
Applied and Environmental Microbiology|January 5, 2002
Comparative genomic analysis of archaeal genotypic variants in a single population and in two different oceanic provincesOded Béjà, Eugene V Koonin, L Aravind, et al.
ACS Pharmacology & Translational Science|February 22, 2021
Single Cell Mass Spectrometry Quantification of Anticancer Drugs: Proof of Concept in Cancer PatientsRyan C Bensen, Shawna J Standke, Devon H Colby, et al.
Antiviral Research|July 5, 2019
Differing activities of oxysterol-binding protein (OSBP) targeting anti-viral compoundsBrett L Roberts, Zachary C Severance, Ryan C Bensen, et al.
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.
Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.
ACS Chemical Biology|December 22, 2018
Transient Compound Treatment Induces a Multigenerational Reduction of Oxysterol-Binding Protein (OSBP) Levels and Prophylactic Antiviral ActivityBrett L Roberts, Zachary C Severance, Ryan C Bensen, et al.
Journal of Medicinal Chemistry|March 14, 2023
Structure-Activity Relationships of Ligand Binding to Oxysterol-Binding Protein (OSBP) and OSBP-Related Protein 4Zachary C Severance, Juan I Nuñez, Anh T Le-McClain, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2013
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activityLeslie W Tari, Michael Trzoss, Daniel C Bensen, et al.
Pageof 3